Phase 4 N=60 DRIVESHAFT: Darunavir/Ritonavir In HIV-infected Virologically-suppressed Experienced Subjects
HIV
Primary: Primary Efficacy Endpoint for Virologic Suppression in HIV-infected Subjects — 27; 25 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.